PDK1 and breast cancer: Previous studies reported that the silencing of PDK1 or DCA treatment causes a metabolic shift from glycolysis to OXPHOS in different types of cancer including head and neck cancer [13], clear-cell renal cell carcinoma [23] and breast cancer [24].